Targets › CYP3A4
11 programs from 11 companies in 14 trials: 6 Phase 4, 3 Phase 2, 3 Phase 1, 2 Phase 3; Infectious disease, Oncology; next expected readout Nov 2026.
A cytochrome P450 monooxygenase involved in the metabolism of sterols, steroid hormones, retinoids and fatty acids. Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). (UniProt, P08684)
Open in Phaseline: the race on CYP3A4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| José Antonio Mata Marín | Darunavir Human immunodeficiency virus type 1 protease inhibitor | CYP3A4, POLB | Phase 4 | HIV Infection | Nov 2026 |
| Instituto Mexicano del Seguro Social | Darunavir Human immunodeficiency virus type 1 protease inhibitor | PROT, CYP3A4, POLR2A | Phase 4 | HIV Infection | Dec 2026 |
| Mount Sinai Hospital, Canada | Ritonavir Human immunodeficiency virus type 1 protease inhibitor; Cytochrome P450 3A inhibitor | CYP3A4, CYP3A5, CYP3A43, CYP3A7 | Phase 4 | SARS CoV-2 Post-Acute Sequelae | Jan 2027 |
| Gilead Sciences | Cobicistat Cytochrome P450 3A inhibitor | CYP3A4, CYP3A5, CYP3A43, CYP3A7 | Phase 4 | HIV-1-infection; AML, Adult | Jun 2027 |
| Nanjing First Hospital, Nanjing Medical University | Vonoprazan-Amoxicillin Dual Therapy Potassium-competitive acid blocker combined with beta-lactam antibiotic for H. pylori erad | CYP3A4 | Phase 4 | HELICOBACTER PYLORI INFECTIONS | – |
| University of Oxford | Ritonavir Human immunodeficiency virus type 1 protease inhibitor; Cytochrome P450 3A inhibitor | CYP3A4, CYP3A5, CYP3A43, CYP3A7 | Phase 3 | Pneumonia; COVID-19 | Jan 2027 |
| Haukeland University Hospital | Ritonavir Human immunodeficiency virus type 1 protease inhibitor; Cytochrome P450 3A inhibitor | CYP3A4, CYP3A5, CYP3A43, CYP3A7 | Phase 3 | Post COVID-19 Condition, Unspecified | Jun 2027 |
| Harvard School of Public Health (HSPH) | Ritonavir Human immunodeficiency virus type 1 protease inhibitor; Cytochrome P450 3A inhibitor | CYP3A4, CYP3A5, CYP3A43, CYP3A7 | Phase 2 | HIV | Jun 2029 |
| Anthony Joshua, FRACP | Itraconazole Cytochrome P450 51 inhibitor | CYP3A4 | Phase 1 | Ovarian Cancer | Jan 2027 |
| University of Wisconsin, Madison | Ritonavir Human immunodeficiency virus type 1 protease inhibitor; Cytochrome P450 3A inhibitor | CYP3A4, CYP3A5, CYP3A43, CYP3A7 | Phase 1 | High-Grade Anal Intraepithelial Neoplasia | Jun 2027 |
| University of Miami | Ritonavir Human immunodeficiency virus type 1 protease inhibitor; Cytochrome P450 3A inhibitor | CYP3A4, CYP3A5, CYP3A43, CYP3A7 | Phase 1 | High Grade Glioma | Apr 2029 |
HIV Infection (3) HIV (1) High-Grade Anal Intraepithelial Neoplasia (1) Post COVID-19 Condition, Unspecified (1) Ovarian Cancer (1) HELICOBACTER PYLORI INFECTIONS (1) SARS CoV-2 Post-Acute Sequelae (1) Pneumonia (1) COVID-19 (1) HIV-1-infection (1) AML, Adult (1) High Grade Glioma (1)
small molecule (9), mixed (2)
Instituto Mexicano del Seguro Social (1) Harvard School of Public Health (HSPH) (1) University of Wisconsin, Madison (1) Haukeland University Hospital (1) Anthony Joshua, FRACP (1) Nanjing First Hospital, Nanjing Medical University (1) Mount Sinai Hospital, Canada (1) José Antonio Mata Marín (1) University of Oxford (1) Gilead Sciences (1) University of Miami (1)
CYP3A5 (7) CYP3A43 (7) CYP3A7 (7) PROT (1) POLR2A (1) POLB (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.